Kombi-Therapie für RNA-Virus-Erkrankungen mit Pyrimidin-Synthesehemmern und Nukleotidanaloga
Die COVID-19-Pandemie hat sich als die schwerste Gesundheitskrise der Neuzeit erwiesen. Zur Bekämpfung von RNA-Virusinfektionen wie SARS, Influenza, Hepatitis C, HIV und sogar Ebola wurde ein neuer kombinierter therapeutischer Ansatz aus Pyrimidin-Analoga und Pyrimidin-Biosynthese-Hemmern entwickelt.
Combination therapy for RNA virus diseases with pyrimidine synthesis inhibitors and nucleotide analogues
The COVID-19 pandemic has emerged as the most serious health crisis in modern times. To combat RNA viral infections like SARS, Influenza, Hepatitis C, HIV or even Ebola a new combination therapeutic approach of pyrimidine analogues and pyrimidine biosynthesis inhibitors has been discovered.
Pan-Coronavirus Therapy using a Cas13-guideRNA system. The antiviral effect is based on an Cas13-guideRNA-AAV vector with up to five guideRNAs, which target and disrupt the genome of the Coronavirus - blocking viral replication. A therapeutic effect was proven in vivo in the SARS-CoV2 Hamster Model.
GMP-compatible Methods for producing tissue-engineered human heart muscle from stem cells
Heart tissue engineering using stem cells is a recently developed technique to construct a three dimensional cell structure from cardiomyocytes or directly from progenitor cells. Scientists at the University of Göttingen developed two new and fully defined methods for serum-free production of engineered human heart muscles.
Treatment of cardiac arrhythmia via re-expression of TBX5 (gene therapy)
Cardiovascular disease is the number one cause of death worldwide. Scientists at the University Medical Center Göttingen developed a gene therapy (TBX5 re-expression) for use in the prevention and acute treatment of a heart disease and associated complications (e.g. cardiac arrhythmia and sudden cardiac death).
Gene therapies are irreversible and not controlable in case of side effects. We offer a pharmacologically controlled one-vector expression system of a therapeutic factor (i.e. GDNF) with zero background expression, based on mifepristone (Mfp)-Gene Switch system, for the therapy of neurological diseases.
Bio-engineered neuronal organoids from human stem cells
Scientists at the University Medical Center Göttingen, Germany developed a reproducible, robust and fully defined method for serum-free production of human bio-engineered neuronal organoids (BENOs) from stem cells. This new method will allow for reproducible production of oganoids with fully functional neuronal network activity.
Improved marker vaccine against classical swine fever
Scientists at the University of Veterinary Medicine Hanover developed a new marker vaccine for classical swine fever based on chimeric pestiviruses with improved DIVA (Differentiating Infected from Vaccinated Animals) properties. The used marker Erns is a chimeric sequence of two different and remotely related pestiviruses.
Due to the large OTOF size a one-vector delivery has remained challenging.Our technology: Gene-therapy of the otoferlin gene (OTOF) with overloaded AAV virus mediated delivery into the cochlea. In vivo proof-of-concept successfully achieved.
All-in-one construct dCas9-TET3CD-(target gene)-sgRNA for targeted fibrosis therapy through demethylation of the genes RASAL1, LRFN2, KLOTHO (i.e. in heart, kidney, liver, lung, cancer). Normal re-expression of these genes has been achieved successfully in vitro and in vivo as well as a reduction of fibrosis.
Therapy of Alzheimer's Disease with an antibody against oligomeric pyro-Glu-Abeta peptides
Scientists at the University of Göttingen developed a novel, proprietary antibody for the therapy and/or diagnosis of Alzheimer's Disease (AD) through the targeting of specifically pyro-Glu-Amyloid beta peptides.
Scientists at the University of Göttingen developed new highly potent drugs (with an IC50 in the pico-molar range) as well as a selective tumor therapy through their prodrugs. Selectivity is achieved by antibody tumor targeting. The highly soluble prodrugs are activated into the cytotoxic drugs only at tumor site.